Edwards Lifesciences Corporation (EW)
NYSE: EW · Real-Time Price · USD
84.49
+1.39 (1.67%)
Jan 15, 2026, 4:00 PM EST - Market closed
Edwards Lifesciences Stock Forecast
Stock Price Forecast
The 19 analysts that cover Edwards Lifesciences stock have a consensus rating of "Buy" and an average price target of $96.37, which forecasts a 14.06% increase in the stock price over the next year. The lowest target is $81 and the highest is $105.
Price Target: $96.37 (+14.06%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Edwards Lifesciences stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 6 | 7 | 6 | 7 |
| Buy | 6 | 5 | 6 | 6 | 7 | 7 |
| Hold | 8 | 6 | 7 | 7 | 7 | 7 |
| Sell | 1 | 1 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 20 | 17 | 19 | 20 | 20 | 21 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| UBS | UBS | Hold Maintains $92 → $95 | Hold | Maintains | $92 → $95 | +12.44% | Jan 12, 2026 |
| Barclays | Barclays | Buy Maintains $103 → $104 | Buy | Maintains | $103 → $104 | +23.09% | Jan 12, 2026 |
| TD Cowen | TD Cowen | Hold → Strong Buy Upgrades $90 → $97 | Hold → Strong Buy | Upgrades | $90 → $97 | +14.81% | Jan 9, 2026 |
| Stifel | Stifel | Strong Buy Maintains $100 → $105 | Strong Buy | Maintains | $100 → $105 | +24.28% | Jan 7, 2026 |
| JP Morgan | JP Morgan | Hold → Buy Upgrades $90 → $100 | Hold → Buy | Upgrades | $90 → $100 | +18.36% | Dec 18, 2025 |
Financial Forecast
Revenue This Year
6.22B
from 5.44B
Increased by 14.29%
Revenue Next Year
6.82B
from 6.22B
Increased by 9.68%
EPS This Year
2.66
from 6.97
Decreased by -61.83%
EPS Next Year
2.95
from 2.66
Increased by 11.03%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 6.4B | 7.1B | ||||
| Avg | 6.2B | 6.8B | ||||
| Low | 5.8B | 6.3B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 17.7% | 14.3% | ||||
| Avg | 14.3% | 9.7% | ||||
| Low | 6.2% | 0.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 2.76 | 3.28 | ||||
| Avg | 2.66 | 2.95 | ||||
| Low | 2.28 | 2.60 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -60.4% | 23.2% | ||||
| Avg | -61.8% | 11.0% | ||||
| Low | -67.2% | -2.4% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.